オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - modafinil, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; pregelatinised maize starch; croscarmellose sodium; povidone; magnesium stearate; microcrystalline cellulose - modavigil is indicated: to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; to treat excessive sleepiness associate with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

apotex nz ltd - selegiline hydrochloride 5mg;  ;  ;   - tablet - 5 mg - active: selegiline hydrochloride 5mg       excipient: lactose monohydrate magnesium stearate microcrystalline cellulose starch

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

astellas pharma us, inc. - gilteritinib fumarate (unii: 5rzz0z1gjt) (gilteritinib - unii:66d92mgc8m) - xospata is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a fms-like tyrosine kinase 3 (flt3) mutation as detected by an fda-approved test. xospata is contraindicated in patients with hypersensitivity to gilteritinib or any of the excipients. anaphylactic reactions have been observed in clinical trials [see adverse reactions (6) and description (11)] . risk summary based on findings from animal studies (see data) and its mechanism of action, xospata can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data on xospata use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, administration of gilteritinib to pregnant rats during organogenesis caused adverse developmental outcomes including embryo-fetal lethality, suppressed fetal growth, and teratogenicity at maternal exposures (auc24 ) approximately 0.4 times the auc

イスラエル - 英語 - Ministry of Health

astellas pharma international b.v., israel - gilteritinib as fumarate - film coated tablets - gilteritinib as fumarate 40 mg - gilteritinib - xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (aml) with a flt3 mutation

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - gilteritinib fumarate, quantity: 44.2 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; mannitol; titanium dioxide; macrogol 8000; hypromellose; purified talc; iron oxide yellow - xospata is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (aml) with a flt3 mutation.

カナダ - 英語 - Health Canada

nu-pharm inc - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

カナダ - 英語 - Health Canada

medican pharma incorporated - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

カナダ - 英語 - Health Canada

pharmascience inc - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

カナダ - 英語 - Health Canada

dominion pharmacal - selegiline hydrochloride - tablet - 5mg - selegiline hydrochloride 5mg - monoamine oxidase b inhibitors

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd), sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330) - ampicillin 100 mg in 1 ml - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus, escherichia coli* , klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis* , bacteroides fragilis* , enterobacter spp.* , and acinetobacter calcoaceticus* . note: for information on use in pediatric patients see precautions-pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli, klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter spp.* gynecological infections caused by beta-lactamase producing strains of escherichia coli*, and bacteroides spp.* (including b. fragilis* ). *efficacy for this organism in this organ system was studied in fewer than 10 infections. while ampicil